Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Deffered Revenue: 2021-2025

Historic Non-Current Deffered Revenue for Viridian Therapeutics, Inc.\DE (VRDN) over the last 3 years, with Jun 2025 value amounting to $140,000.

  • Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue fell 67.29% to $140,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $140,000, marking a year-over-year decrease of 67.29%. This contributed to the annual value of $284,000 for FY2024, which is 50.44% down from last year.
  • According to the latest figures from Q2 2025, Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue is $140,000, which was down 33.96% from $212,000 recorded in Q1 2025.
  • Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue's 5-year high stood at $1.1 million during Q4 2021, with a 5-year trough of $140,000 in Q2 2025.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $464,000 (2024), whereas its average is $464,400.
  • Data for Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue shows a maximum YoY slumped of 67.29% (in 2025) over the last 5 years.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue (Quarterly) stood at $1.1 million in 2021, then dropped by 25.07% to $861,000 in 2022, then plummeted by 33.45% to $573,000 in 2023, then crashed by 50.44% to $284,000 in 2024, then tumbled by 67.29% to $140,000 in 2025.
  • Its last three reported values are $140,000 in Q2 2025, $212,000 for Q1 2025, and $284,000 during Q4 2024.